Terumo Corporation
TSE-4543
Company Overview
Terumo Corporation engages in the manufacture and sale of medical products and equipment worldwide. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company. The Cardiac and Vascular Company segment offers angiographic guidewires, angiographic catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, self-expanding peripheral stents, intravascular ultrasound systems, imaging catheters, and others; coils, stents, and intrasaccular devices for treating cerebral aneurysm; embolization systems, aspiration catheters, and clot retrievers for treating ischemic stroke and others; oxygenators, cardio-pulmonary bypass systems, and others; and artificial vascular and stent grafts. The Medical Care Solutions Company segment provides syringes, infusion pumps, syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, pain management and nutritious food products, adhesion barriers, and others; blood glucose monitoring systems, disposable needles for pen-injector, insulin patch pumps, blood pressure monitors, digital thermometers, and others; and contract manufacturing of prefilled syringes, devices to pharmaceutical companies for use in drug kits, such as prefillable syringes, needles for pharmaceutical packaging business, and others. The Blood and Cell Technologies Company segment offers blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, cell expansion systems, and others. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was incorporated in 1921 and is headquartered in Tokyo, Japan.
Name
Terumo Corporation
CEO
Mr. Hikaru Samejima
Website
www.terumo.com
Sector
Health Care Equipment and Supplies
Year Founded
1921
Profile
Market Cap
¥3,871.23B
EV
¥3,910.99B
Shares Out
1,484.94M
Revenue
¥964.81B
Employees
—
Margins
Gross
52.74%
EBITDA
22.36%
Operating
16.12%
Pre-Tax
16.24%
Net
12.2%
FCF
11.32%
Returns (5Yr Avg)
ROA
6.38%
ROTA
20.4%
ROE
9.75%
ROCE
9.72%
ROIC
8.01%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
¥3,215.38
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
¥194.91B
Net Debt
¥39.76B
Debt/Equity
0.17
EBIT/Interest
71.06
Growth (CAGR)
Rev 3Yr
—
Rev 5Yr
—
Rev 10Yr
7.03%
Dil EPS 3Yr
—
Dil EPS 5Yr
—
Dil EPS 10Yr
12.28%
Rev Fwd 2Yr
8.49%
EBITDA Fwd 2Yr
12.93%
EPS Fwd 2Yr
18.02%
EPS LT Growth Est
18.39%
Dividends
Yield
—
Payout
27.79%
DPS
¥22
DPS Growth 3Yr
—
DPS Growth 5Yr
—
DPS Growth 10Yr
11.74%
DPS Growth Fwd 2Yr
16.95%